Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11298MR)

This product GTTS-WQ11298MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11298MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4839MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ4966MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ2683MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ3518MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ10341MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ3207MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ14023MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12269MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW